1. Low anti‐SARS‐CoV‐2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID‐19 patients.
- Author
-
Martin‐Vicente, María, Almansa, Raquel, Martínez, Isidoro, Tedim, Ana P., Bustamante, Elena, Tamayo, Luis, Aldecoa, César, Gómez, José Manuel, Renedo, Gloria, Berezo, Jose Ángel, Cedeño, Jamil Antonio, Mamolar, Nuria, García Olivares, Pablo, Herrán‐Monge, Rubén, Cicuendez, Ramón, Enríquez, Pedro, Ortega, Alicia, Jorge, Noelia, Doncel, Cristina, and de la Fuente, Amanda
- Subjects
COVID-19 ,VIRAL antibodies ,IMMUNOGLOBULINS ,MORTALITY ,VIRAL replication - Abstract
Background: Anti‐SARS‐CoV‐2 S antibodies prevent viral replication. Critically ill COVID‐19 patients show viral material in plasma, associated with a dysregulated host response. If these antibodies influence survival and viral dissemination in ICU‐COVID patients is unknown. Patients/Methods: We studied the impact of anti‐SARS‐CoV‐2 S antibodies levels on survival, viral RNA‐load in plasma, and N‐antigenaemia in 92 COVID‐19 patients over ICU admission. Results: Frequency of N‐antigenaemia was >2.5‐fold higher in absence of antibodies. Antibodies correlated inversely with viral RNA‐load in plasma, representing a protective factor against mortality (adjusted HR [CI 95%], p): (S IgM [AUC ≥ 60]: 0.44 [0.22; 0.88], 0.020); (S IgG [AUC ≥ 237]: 0.31 [0.16; 0.61], <0.001). Viral RNA‐load in plasma and N‐antigenaemia predicted increased mortality: (N1‐viral load [≥2.156 copies/ml]: 2.25 [1.16; 4.36], 0.016); (N‐antigenaemia: 2.45 [1.27; 4.69], 0.007). Conclusions: Low anti‐SARS‐CoV‐2 S antibody levels predict mortality in critical COVID‐19. Our findings support that these antibodies contribute to prevent systemic dissemination of SARS‐CoV‐2. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF